These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

198 related items for PubMed ID: 9119160

  • 1. Strategy for adventitious agent assays.
    Robertson JS.
    Dev Biol Stand; 1996; 88():37-40. PubMed ID: 9119160
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Process scale considerations in evaluation studies and scale-up.
    Walter JK, Werz W, Berthold W.
    Dev Biol Stand; 1996; 88():99-108. PubMed ID: 9119169
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Use of bacteriophages as surrogates for mammalian viruses.
    McAlister M, Aranha H, Larson R.
    Dev Biol (Basel); 2004; 118():89-98. PubMed ID: 15645677
    [Abstract] [Full Text] [Related]

  • 10. Experiences of virus, retrovirus and retrovirus-like particles in Chinese hamster ovary (CHO) and hybridoma cells used for production of protein therapeutics.
    Adamson SR.
    Dev Biol Stand; 1998; 93():89-96. PubMed ID: 9737383
    [Abstract] [Full Text] [Related]

  • 11. Current issues in viral assays and viral clearance evaluation.
    Lubiniecki AS.
    Dev Biol Stand; 1996; 88():9-11. PubMed ID: 9119167
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Evolution of approaches to viral safety issues for biological products.
    Lubiniecki AS.
    PDA J Pharm Sci Technol; 2011; 65(6):547-56. PubMed ID: 22294576
    [Abstract] [Full Text] [Related]

  • 14. Scope and practicality of in vivo testing for adventitious agents.
    Whiteman MD.
    Dev Biol (Basel); 2006; 123():147-52; discussion 183-97. PubMed ID: 16566442
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Relationship between nature and source of risk and process validation.
    Berthold W, Werz W, Walter JK.
    Dev Biol Stand; 1996; 88():59-71. PubMed ID: 9119164
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Retrovirus screening of vaccine cell substrates.
    Khan AS.
    Dev Biol Stand; 1996; 88():157-62. PubMed ID: 9119131
    [Abstract] [Full Text] [Related]

  • 20. Proceedings of the 2017 Viral Clearance Symposium Session 5: Facility Risk Mitigation.
    Ma J, Kreil TR.
    PDA J Pharm Sci Technol; 2018; 72(5):511-515. PubMed ID: 30030359
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.